Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in moderate to severe chronic plaque psoriasis (IMMhance)
NCT02672852Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2016
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc.. Started Feb 2016; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02672852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672852.